2 Stocks to Buy Near Their 52-Week Lows

Pinterest reported Q3 revenue up 17% year-over-year to roughly $1.0 billion with EPS of $0.13 (vs. $0.04 a year ago), ARPU +5% to $1.78, 600 million MAUs (+12% YoY) and free cash flow of $318.4 million (+30% YoY), but missed EPS expectations, issued disappointing guidance and flagged tariff-related ad demand headwinds even as AI-driven product and ad improvements and Gen Z user growth support long-term monetization. Zoetis is seeing weaker-than-expected sales for newer OA drugs Librela and Solensia but benefits from strength in legacy product Apoquel and a deep portfolio (17 products >$100M, ~300 lines), large addressable dermatology opportunity (est. >20M untreated dogs vs ~12M reached) and a history of dividend growth (payouts +426.3% over the past decade), making both names presented as potential long-term buys near 52-week lows.

Analysis

Market structure: Pinterest (PINS) and Zoetis (ZTS) move opposite supply-demand forces—PINS faces cyclical ad-demand erosion from tariff-hit retailers but shows structural ARPU (+5% YoY) and FCF strength (+30% YoY to $318m) driven by AI search/ads; ZTS suffers product adoption hiccups (Librela/Solensia) but retains durable pricing power across >300 product lines and 17 >$100m products. Expect ad-revenue-sensitive midcaps to underperform short-term while select defensives in animal health capture flows.

Risk assessment: Near-term tail risks include prolonged tariff-induced retail ad cuts (0–3 months) and regulatory/safety setbacks for animal drug uptake (3–12 months); low-probability high-impact: a major safety recall for Librela/Solensia could erase 12–18 months of growth. Monitor two quantifiable triggers: retail ad spend reacceleration (quarterly revenue beat +3% vs guide) and vet prescription trends (monthly script growth >10% for Librela over two consecutive quarters).

Trade implications: Tactical plays—favor small, staged longs: PINS for asymmetric upside via 9–12 month LEAP calls (target 15–25% absolute upside), ZTS as a 3–4% core dividend holding with covered-call overlay to boost yield. Pair trade opportunity: long ZTS vs short SNAP (ad cyclicality mismatch) on a 6–12 month horizon; size 1–2% net exposure and cut if spread narrows >15%.

Contrarian angles: Consensus underestimates the speed AI can convert engagement into ARPU (+10–20% CAGR potential over 12–24 months), so PINS could re-rate faster than peers if tariffs ease. Conversely, the market may be underpricing multi-year upside in ZTS from unmet treatment pool (20m untreated dogs vs 12m treated) — a slower 6–12 month commercial ramp could still deliver durable returns; downside is overdose of short-term disappointment priced in today.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in PINS via Jan-2026 LEAP calls ~15% OTM (or equivalent stock position if options unavailable). Scale in over 4–8 weeks and place a hard stop / hedge if PINS falls >18% from entry or if Q next-quarter ad guide misses by >5%.
• Add a 3–4% core position in ZTS for dividend+growth; implement a covered-call program selling 3-month calls 6–8% OTM to boost yield. If Librela/Solensia monthly scripts do not show sequential improvement over two quarters, trim exposure by 50%.
• Implement a relative-value pair: long ZTS (1–2%) vs short SNAP (1–2%) targeting convergence over 6–12 months; close the pair if ZTS underperforms SNAP by >15% or if SNAP reports MAU/ARPU beats for two consecutive quarters.
• Monitor tariff negotiations and retail ad guidance over the next 30–60 days: if tariffs remain unresolved and retail ad guidance declines >5% QoQ, reduce ad-revenue-exposed tech positions (e.g., SNAP, META) by ~15% and rotate proceeds into defensive healthcare/animal health (increase ZTS weight by 1–2%).